BeyondSpring Inc

NASDAQ:BYSI   12:08:42 PM EDT
11.11
-0.05 (-0.45%)
Products

Beyondspring Announces U.S. FDA Acceptance And Priority Review Of New Drug Application For Plinabulin And G-Csf Combination For The Prevention Of Chemotherapy-Induced Neutropenia (Cin)

Published: 06/01/2021 13:41 GMT
BeyondSpring Inc (BYSI) - Beyondspring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-csf Combination for the Prevention of Chemotherapy-induced Neutropenia (cin).
Beyondspring Inc - FDA Has Set a PDUFA Target Action Date for November 30, 2021.